Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic.
Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development.
Each one of us together for patients
We believe our modular approach to selecting our in vivo and ex vivo programs positions us to build a full-spectrum genome editing company, with a pipeline across a range of indications. This approach enables us to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases.
#HAE is a rare genetic disorder characterized by recurrent episodes of debilitating and potentially fatal swelling in various parts of the body. Learn more about our approach to treating this condition using #CRISPR/Cas9: https://t.co/skagAH8dyk https://t.co/jEa4mTlqEw
#ICYMI Intellia CSO, @LauraSepplore, was recently a guest on @BioAgilytix’s podcast, Molecular Moments, discussing her path from Argentina to the U.S., gene therapy vs. #genomeediting and the work we’re doing at Intellia. Listen here: https://t.co/vnXn2AC4Wd https://t.co/UKS9Jgwn5N